Uni-Bio's osteoporosis candidate achieves phase III endpoint
By Shannon Ellis
Wednesday, July 2, 2014
SHANGHAI Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in post-menopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.